Cita APA

Reinmuth, N., Bryl, M., Bondarenko, I., Syrigos, K., Vladimirov, V., Zereu, M., . . . Kasahara, K. (2019). PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin(®)), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. BioDrugs.

Chicago Style Citation

Reinmuth, Niels, et al. "PF-06439535 (a Bevacizumab Biosimilar) Compared With Reference Bevacizumab (Avastin(®)), Both Plus Paclitaxel and Carboplatin, As First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study." BioDrugs 2019.

Cita MLA

Reinmuth, Niels, et al. "PF-06439535 (a Bevacizumab Biosimilar) Compared With Reference Bevacizumab (Avastin(®)), Both Plus Paclitaxel and Carboplatin, As First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study." BioDrugs 2019.